ArticleCardiovascular research2025
A new protein isoform encoded by human circular RNA circSLC8a1 contributes to cardiac remodelling.
Article in Cardiovascular research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Circular RNA as emerging precision therapeutics: from RNA regulation to peptide translation.Precision clinical medicine · 2026Review
- The regulatory roles and therapeutic strategies of the solute carrier transporters in cancer metabolism.NPJ precision oncology · 2026Review
- Micropeptides Encoded by Noncoding RNAs: Biological Functions and Roles in Diseases.Research (Washington, D.C.) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
aimsCircular RNA circSLC8a1 has been previously suggested to possess translation potential, but experimental evidence supporting this notion has been lacking. We aim to understand the functions of circSLC8a1 and its translated protein in cardiac remodelling. METHODS AND
resultsTo elucidate the functional significance of circSLC8a1, we established a transgenic mouse line expressing circSLC8a1 and its translated protein SLC8a1-604. We present compelling evidence confirming the translation potential of circSLC8a1 (hsa_circ_0005232) both in vitro and in vivo. The back-splicing event within hsa_circ_0005232 leads to the generation of a novel circRNA-derived protein comprising 604 amino acids, named SLC8a1-604, which has not been previously reported. These SLC8a1-604 transgenic mice exhibited a heart failure phenotype. In further investigations, we induced pressure overload in the transgenic mice, revealing a significant decrease in heart function compared to litter-matched negative controls. Notably, our findings indicate that the reduced heart function observed in the transgenic mice can be attributed to the presence of the circRNA-translated protein, SLC8a1-604, rather than the circRNA itself. Mechanistically, we found that SLC8a1-604 translocated into mitochondria, where it exerted its effects by binding to POLRMT. This interaction results in a downregulation of mitochondrial gene transcription, leading to a decrease in ATP synthesis.
conclusionOur study provides evidence that circSLC8a1 has the capacity to encode a novel protein isoform, SLC8a1-604, which plays a pivotal role in the regulation of heart functions: circSLC8a1 modulates the remodelling process of cardiac pressure overload by translating into a functional protein.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.